Allogene Therapeutics Inc (NAS:ALLO)
$ 2.14 -0.05 (-2.28%) Market Cap: 459.18 Mil Enterprise Value: 269.53 Mil PE Ratio: 0 PB Ratio: 0.99 GF Score: 37/100

Allogene Therapeutics Inc at Bank of America Healthcare Conference Transcript

May 10, 2022 / 03:00PM GMT
Release Date Price: $7.67 (+4.64%)
Jason Matthew Gerberry
BofA Securities, Research Division - MD in US Equity Research

Thanks for joining us this morning at the Bank of America Annual Healthcare Conference in Las Vegas. I am Jason Gerberry. I'm one of the biotech analysts at BofA. And I am pleased to be introducing our next -- our first company presenter, Allogene Therapeutics and Eric Schmidt, CFO.

Eric, I think, has a couple of prepared remarks, and then we'll go right into Q&A from there.

Eric Thomas Schmidt
Allogene Therapeutics, Inc. - CFO

Thank you, Jason. Thanks for the invitation. Thanks to Bank of America for hosting myself and our Chief Commercial Officer, Christine Cassiano, who's here in the front row. And thanks, everyone, for getting up early to kick off this conference. I appreciate those on the webcast as well.

In terms of a quick background on Allogene, Matthew, we have just one slide I'd like to present for those a little less familiar to our story. We're a 4-year-old company. In fact, we celebrated our fourth anniversary just earlier this year. We

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot